Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-PRF (Leukocyte- and Platelet-Rich Fibrin) is an autologous, second-generation platelet concentrate used as a biological scaffold in regenerative medicine. Developed from the patient's own blood, it contains a dense fibrin matrix enriched with leukocytes and platelets. This biomaterial acts as a reservoir for the sustained release of growth factors, such as transforming growth factor-beta (TGF-β), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF), which are critical for tissue regeneration, angiogenesis, and wound healing. In the context of periodontology, Universitaire Ziekenhuizen KU Leuven is evaluating L-PRF for the surgical treatment of periodontal intra-bony defects to promote bone and soft tissue repair.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on L-PRF.